The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs
remains one of the key challenges in cancer research. Despite its relevance, no efficient …

Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic
activity toward a plethora of clinically important medications. Thus, single nucleotide variants …

Renal cell carcinoma (RCC) is a complex disease characterized by mutations in several
genes. Loss of function of the von Hippel-Lindau (VHL) tumour suppressor gene is a very …

The extensive use of tyrosine kinase inhibitors (TKI's) in hematology and oncology has
shown that these drugs have a significant potential for drug‐drug interactions. Since these …

A number of molecularly targeted anticancer drugs that efficiently inhibit receptor tyrosine
kinases, socalled receptor tyrosine kinase inhibitors (TKIs), have been developed. Although …

Inter-ethnic differences in systemic exposure, efficacy and safety have been reported for
some small molecule tyrosine kinase inhibitors (smTKIs). This variability in response related …

Background: An increasing number of studies have reported ethnic differences in sunitinib
outcome in metastatic renal cell carcinoma (mRCC) patients. However, a comprehensive …

Once universally considered a rapidly fatal condition, cancer has increasingly become a
chronic medical condition and comorbidities and adverse effects of cancer therapies have …

The tyrosine kinase inhibitor sunitinib is used as first‐line therapy in patients with
metastasized renal cell carcinoma (mRCC), given in fixed‐dose regimens despite its high …

The single nucleotide polymorphism (SNP) rs4646437G> A in CYP3A4 was suggested to be
related to sunitinib toxicity. Our objective was to perform an in-depth investigation of the …